Unique ID issued by UMIN | UMIN000053426 |
---|---|
Receipt number | R000060975 |
Scientific Title | VEXAS Syndrome Registry and Repository |
Date of disclosure of the study information | 2024/01/24 |
Last modified on | 2024/01/24 15:05:58 |
VEXAS Syndrome Registry and Repository
VEXAS Syndrome Registry and Repository
VEXAS Syndrome Registry and Repository
VEXAS Syndrome Registry and Repository
Japan |
VEXAS syndrome
Medicine in general | Pneumology | Hematology and clinical oncology |
Clinical immunology | Dermatology |
Others
YES
To investigate the clinical presentation, natural history, treatment, prognosis, and genotype of VEXAS syndrome.
Others
To elucidate the pathogenesis of VEXAS syndrome.
Exploratory
Pragmatic
Not applicable
Life Prognosis of Patients with VEXAS Syndrome
Symptoms, medications, hospitalization, complications
Observational
Not applicable |
Not applicable |
Male and Female
2 points for macrocytic anemia, 1 point for chondritis, 1 point for pulmonary infiltrates, 1 point for skin rash, 1 point for age 50 or older, total of at least 3 points
None
100
1st name | Yohei |
Middle name | |
Last name | Kirino |
Yokohama City University Graduate School of Medicine
Department of Stem Cell and Immune Regulation
236-0004
3-9 Fukuura, Kanazawa-Ku, Yokohama
+81-45-787-2800
kirino@yokohama-cu.ac.jp
1st name | Yohei |
Middle name | |
Last name | Kirino |
Yokohama City University Graduate School of Medicine
Department of Stem Cell and Immune Regulation
236-0004
3-9 Fukuura, Kanazawa-Ku, Yokohama
+81-45-787-2800
kirino@yokohama-cu.ac.jp
Yokohama City University Graduate School of Medicine
Yokohama City University Graduate School of Medicine
Other
Ethics Officer, Yokohama City University
3-9 Fukuura, Kanazawa-Ku, Yokohama
045-370-7627
rinri@yokohama-cu.ac.jp
NO
2024 | Year | 01 | Month | 24 | Day |
Unpublished
Enrolling by invitation
2023 | Year | 01 | Month | 10 | Day |
2023 | Year | 02 | Month | 24 | Day |
2023 | Year | 09 | Month | 01 | Day |
2030 | Year | 03 | Month | 31 | Day |
Background information: age, gender, height, weight, smoking history, drinking history, medical history, comorbidities, IPSS score
Clinical manifestations of VEXAS syndrome: skin rash, arthritis, lung involvement, chondritis, vasculitis, myelodysplastic syndrome symptoms, eyelid edema, eye
involvement, steroid-resistant inflammation
Treatment of VEXAS syndrome and duration: use of steroids, immunosuppressive drugs, biologics, or other agents
Blood test results: preoperative, postoperative, and at outpatient follow-up: hematology: white blood cell count, neutrophil count, monocyte count, lymphocyte count, MCV, MCHC, RDW, hemoglobin, hematocrit, reticulocyte count, platelets; biochemical tests: total protein, serum albumin, total serum albumin, total serum
2024 | Year | 01 | Month | 24 | Day |
2024 | Year | 01 | Month | 24 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000060975
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |